[Glargine insulin and cancer risk].
Rigla Cros
Mercedes
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D048909:Diabetes Complications / Q000139:chemically induced / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D051381:Rats; D055815:Young Adult
D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D008687:Metformin